{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T23:35:55Z","timestamp":1776209755680,"version":"3.50.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Tubo-ovarian carcinoma, a leading cause of gynaecological-related mortality, holds substantial biological and clinical heterogeneity. Despite advancements in drug development, predicting therapeutic efficacy remains challenging, partly due to the limited availability of in vitro models that accurately replicate tumour behaviour. We present a concise overview of the intrahospital workflow for establishing patient-derived organoids and analyse the morphological and immunophenotypical features of high-grade serous carcinoma (HGSC), serous borderline tumour (SBT)\/low-grade serous carcinoma (LGSC), and normal fallopian tube (FT) organoids.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Samples were collected from patients undergoing surgery or paracentesis. Tissue underwent mechanical and enzymatical digestion. Resulting cell suspensions were resuspended in an extracellular matrix substitute for subsequent culture. Despite the low efficacy in establishing HGSC organoids (<jats:italic>n<\/jats:italic>\u2009=\u20091\/7, 14%; 96 days, 11 passages), we successfully established two organoid lines of SBT\/LGSC (<jats:italic>n<\/jats:italic>\u2009=\u20092\/2, 100%; 65 days, 7 passages; 134 days, 16 passages) and normal FT (<jats:italic>n<\/jats:italic>\u2009=\u20092\/2, 100%; 73 days, 10 passages; 58 days, 8 passages). HGSC organoids exhibited limited growth and mostly irregular structures, while preserving the p53 immunostaining pattern of the original tumour. SBT\/LGSC and FT organoids maintained features of architectural complexity and faithfully recapitulated the original immunoprofile.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study highlights the need for a multidisciplinary collaboration in both clinical and research settings to establish patient-derived organoids. It emphasises the pivotal contribution of pathologists in meticulous sampling and organoid characterisation. The integration of diverse expertise is essential for maximising the potential of organoids as preclinical tools, advancing our understanding of tubo-ovarian carcinoma, and ultimately improving patient outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13048-025-01766-4","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T04:59:38Z","timestamp":1755665978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patient-derived organoids as a model to study tubo-ovarian carcinoma: a pathologist\u2019s perspective"],"prefix":"10.1186","volume":"18","author":[{"given":"Catarina","family":"Alves-Vale","sequence":"first","affiliation":[]},{"given":"Beatriz","family":"Galv\u00e3o","sequence":"additional","affiliation":[]},{"given":"Ana Rita","family":"Silvestre","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Silva","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Li","family":"Bei","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Paulo","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Borralho","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Carmo-Fonseca","sequence":"additional","affiliation":[]},{"given":"No\u00e9lia","family":"Cust\u00f3dio","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"1766_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1766_CR2","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393:1240\u201353.","journal-title":"Lancet"},{"key":"1766_CR3","volume-title":"WHO classification of tumours - Female genital tumours","author":"AN Cheung","year":"2020","unstructured":"Cheung AN, Ellenson LH, Gilks CB, Kim K-R, Kong CS, Lax SF, et al. Tumours of the ovary. editor. WHO classification of tumours - Female genital tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2020. WHO Classification of Tumours Editorial Board.","edition":"5"},{"key":"1766_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2018.06.018","volume":"80","author":"J Prat","year":"2018","unstructured":"Prat J, D\u2019Angelo E, Espinosa I. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular. Hum Pathol. 2018;80:11\u201327.","journal-title":"Hum Pathol"},{"issue":"4","key":"1766_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","volume":"186","author":"RJ Kurman","year":"2016","unstructured":"Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis revisited, revised, and expanded. Am J Pathol. 2016;186(4):733\u201347.","journal-title":"Am J Pathol"},{"issue":"5","key":"1766_CR6","first-page":"672","volume":"30","author":"N Colombo","year":"2019","unstructured":"Colombo N, Sessa C, Bois A, Ledermann J, Mccluggage WG, Mcneish I, et al. ESMO \u2013 ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. 2019;30(5):672\u2013705.","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"1766_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","volume":"28","author":"A Malpica","year":"2004","unstructured":"Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, et al. Grading ovarian serous carcinoma using a Two-Tier system. Am J Surg Pathol. 2004;28(4):496\u2013504.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"1766_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/path.3023","volume":"226","author":"E Kuhn","year":"2012","unstructured":"Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol. 2012;226(3):421\u20136.","journal-title":"J Pathol"},{"issue":"1","key":"1766_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-01217-9","volume":"8","author":"J Ducie","year":"2017","unstructured":"Ducie J, Dao F, Considine M, Olvera N, Shaw PA, Kurman RJ, et al. Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nat Commun. 2017;8(1):1\u20139.","journal-title":"Nat Commun"},{"issue":"1","key":"1766_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/GCO.0b013e328011a21f","volume":"19","author":"CP Crum","year":"2007","unstructured":"Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19(1):3\u20139.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"7","key":"1766_CR11","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","volume":"42","author":"RJ Kurman","year":"2011","unstructured":"Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - Shifting the paradigm. Hum Pathol. 2011;42(7):918\u201331.","journal-title":"Hum Pathol"},{"issue":"Suppl","key":"1766_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/annonc\/mdt463","volume":"24","author":"RJ Kurman","year":"2013","unstructured":"Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 2013;24(Suppl):16\u201321.","journal-title":"Ann Oncol"},{"issue":"4","key":"1766_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrclinonc.2015.224","volume":"13","author":"S Narod","year":"2016","unstructured":"Narod S. Can advanced-stage ovarian cancer be cured? Nat Rev Clin Oncol. 2016;13(4):255\u201361.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"1766_CR14","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/modpathol.2011.106","volume":"24","author":"J Li","year":"2011","unstructured":"Li J, Abushahin N, Pang S, Xiang L, Chambers SK, Fadare O, et al. Tubal origin of ovarian low-grade serous carcinoma. Mod Pathol. 2011;24(11):1488\u201399.","journal-title":"Mod Pathol"},{"issue":"9","key":"1766_CR15","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1097\/PAS.0000000000000693","volume":"40","author":"G Ahn","year":"2016","unstructured":"Ahn G, Folkins AK, McKenney JK, Longacre TA. Low-grade serous carcinoma of the ovary: clinicopathologic analysis of 52 invasive cases and identification of a possible noninvasive intermediate lesion. Am J Surg Pathol. 2016;40(9):1165\u201376.","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"1766_CR16","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1136\/ijgc-2023-004610","volume":"33","author":"RN Grisham","year":"2023","unstructured":"Grisham RN, Slomovitz BM, Andrews N, Banerjee S, Brown J, Carey MS, et al. Low-grade serous ovarian cancer: expert consensus report on the state of the science. Int J Gynecol Cancer. 2023;33(9):1331\u201344.","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"1766_CR17","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","volume":"31","author":"RE Miller","year":"2020","unstructured":"Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020;31(12):1606\u201322.","journal-title":"Ann Oncol"},{"key":"1766_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.semcancer.2021.02.008","volume":"77","author":"IG Funingana","year":"2021","unstructured":"Funingana IG, Reinius MAV, Petrillo A, Ang JE, Brenton JD. Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer? Semin Cancer Biol. 2021;77:67\u201382.","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"1766_CR19","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","volume":"165","author":"H Clevers","year":"2016","unstructured":"Clevers H. Modeling development and disease with organoids. Cell. 2016;165(7):1586\u201397.","journal-title":"Cell"},{"issue":"7","key":"1766_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18(7):407\u201318.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"1766_CR21","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.medj.2024.08.010","volume":"5","author":"L Tong","year":"2024","unstructured":"Tong L, Cui W, Zhang B, Fonseca P, Zhao Q, Zhang P, et al. Patient-derived organoids in precision cancer medicine. Med. 2024;5(11):1351\u201377.","journal-title":"Med"},{"issue":"7","key":"1766_CR22","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s12276-024-01272-5","volume":"56","author":"L Thorel","year":"2024","unstructured":"Thorel L, Perr\u00e9ard M, Florent R, Divoux J, Coffy S, Vincent A, et al. Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology. Exp Mol Med. 2024;56(7):1531\u201351.","journal-title":"Exp Mol Med"},{"issue":"11","key":"1766_CR23","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","volume":"8","author":"SJ Hill","year":"2018","unstructured":"Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG Jr. Prediction of DNA repair inhibitor response in Short-Term Patient-Derived ovarian cancer organoids. Cancer Discov. 2018;8(11):1404\u201321.","journal-title":"Cancer Discov"},{"key":"1766_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2014.06.005","volume":"79\u201380","author":"G Benton","year":"2014","unstructured":"Benton G, Arnaoutova I, George J, Kleinman HK, Koblinski J. Matrigel: from discovery and ECM mimicry to assays and models for cancer research. Adv Drug Deliv Rev. 2014;79\u201380:3\u201318.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"1766_CR25","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/PAS.0b013e3181da7687","volume":"34","author":"AR Laury","year":"2010","unstructured":"Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010;34(5):627\u201335.","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"1766_CR26","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/modpathol.2011.3","volume":"24","author":"A Ozcan","year":"2011","unstructured":"Ozcan A, Shen SS, Hamilton C, Anjana K, Coffey D, Krishnan B, et al. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: A comprehensive immunohistochemical study. Mod Pathol. 2011;24(6):751\u201364.","journal-title":"Mod Pathol"},{"key":"1766_CR27","doi-asserted-by":"crossref","unstructured":"Seidman JD, Ronnett BM, Shih I-M, Cho KR, Kurman RJ. Epithelial tumors of the ovary. In: Kurman RJ, Ellenson LH, Ronnett BM, editors. Blaustein\u2019s pathology of the female genital tract. 7th ed. Springer; 2019. pp. 841\u2013966.","DOI":"10.1007\/978-3-319-46334-6_14"},{"issue":"11","key":"1766_CR28","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1097\/01.pas.0000176429.88702.36","volume":"29","author":"C Tornos","year":"2005","unstructured":"Tornos C, Soslow R, Chen S, Akram M, Hummer AJ, Abu-Rustum N, et al. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol. 2005;29(11):1482\u20139.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1766_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/PGP.0000000000000207","volume":"35","author":"R Vang","year":"2016","unstructured":"Vang R, Levine DA, Soslow RA, Zaloudek C, Shih IM, Kurman RJ. Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: A rereview of cases lacking TP53 mutations in the cancer genome atlas ovarian study. Int J Gynecol Pathol. 2016;35(1):48\u201355.","journal-title":"Int J Gynecol Pathol"},{"issue":"7353","key":"1766_CR30","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"The Cancer Genome Atlas Network","year":"2011","unstructured":"The Cancer Genome Atlas Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609\u201315.","journal-title":"Nature"},{"issue":"Suppl 1","key":"1766_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/PGP.0000000000000488","volume":"38","author":"M K\u00f6bel","year":"2019","unstructured":"K\u00f6bel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG. Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility. Int J Gynecol Pathol. 2019;38(Suppl 1):123\u201331.","journal-title":"Int J Gynecol Pathol"},{"key":"1766_CR32","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/cjp2.53","volume":"2","author":"M K\u00f6bel","year":"2016","unstructured":"K\u00f6bel M, Piskorz AM, Lee S, Lui S, Lepage C, Marass F, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res. 2016;2:247\u201358.","journal-title":"J Pathol Clin Res"},{"issue":"2","key":"1766_CR33","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/01.pas.0000146025.91953.8d","volume":"29","author":"G Singer","year":"2005","unstructured":"Singer G, St\u00f6hr R, Cope L, Dehari R, Hartmann A, Cao DF, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: A mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;29(2):218\u201324.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"1766_CR34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ygyno.2006.08.052","volume":"104","author":"NJ Bowen","year":"2007","unstructured":"Bowen NJ, Logani S, Dickerson EB, Kapa LB, Akhtar M, Benigno BB, et al. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol. 2007;104(2):331\u20137.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"1766_CR35","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","volume":"24","author":"R Perets","year":"2013","unstructured":"Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, et al. Transformation of the fallopian tube secretory epithelium leads to High-Grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell. 2013;24(6):751\u201365.","journal-title":"Cancer Cell"},{"issue":"2","key":"1766_CR36","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ccell.2020.01.003","volume":"37","author":"Z Hu","year":"2020","unstructured":"Hu Z, Artibani M, Alsaadi A, Wietek N, Morotti M, Shi T, et al. The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells. Cancer Cell. 2020;37(2):226\u2013e2427.","journal-title":"Cancer Cell"},{"issue":"10","key":"1766_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41596-020-0379-4","volume":"15","author":"E Driehuis","year":"2020","unstructured":"Driehuis E, Kretzschmar K, Clevers H. Establishment of patient-derived cancer organoids for drug-screening applications. Nat Protoc. 2020;15(10):1\u201330.","journal-title":"Nat Protoc"},{"key":"1766_CR38","doi-asserted-by":"publisher","first-page":"8989","DOI":"10.1038\/ncomms9989","volume":"6","author":"M Kessler","year":"2015","unstructured":"Kessler M, Hoffmann K, Brinkmann V, Thieck O, Jackisch S, Toelle B, et al. The Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids. Nat Commun. 2015;6:8989.","journal-title":"Nat Commun"},{"key":"1766_CR39","doi-asserted-by":"crossref","unstructured":"Del Valle JS, Husetic A, Diek D, Rutgers LF, Asseler JD, Metzemaekers J et al. Human ovarian surface epithelium organoids as a platform to study tissue regeneration. JoVE [Internet]. 2024(210):e66797.","DOI":"10.3791\/66797"},{"issue":"3","key":"1766_CR40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00432-024-05654-0","volume":"150","author":"C Nero","year":"2024","unstructured":"Nero C, Vizzielli G, Lorusso D, Cesari E, Daniele G, Loverro M, et al. Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine. J Cancer Res Clin Oncol. 2024;150(3):146.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"1766_CR41","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s00432-024-05654-0","volume":"150","author":"H Hu","year":"2024","unstructured":"Hu H, Sun C, Chen J, Li Z. Organoids in ovarian cancer: a platform for disease modeling, precision medicine, and drug assessment. J Cancer Res Clin Oncol. 2024;150(3):146.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"1766_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/path.2696","volume":"221","author":"AA Ahmed","year":"2010","unstructured":"Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221(1):49\u201356.","journal-title":"J Pathol"},{"key":"1766_CR43","doi-asserted-by":"crossref","unstructured":"Uruski P, Sepetowska A, Konieczna C, Paku\u0142a M, Wyrwa M, Tussupkaliyev A et al. Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and Paclitaxel in vitro. Cell Mol Biol Lett. 2021;26(1).","DOI":"10.1186\/s11658-021-00287-4"},{"issue":"4","key":"1766_CR44","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.stemcr.2020.03.004","volume":"14","author":"N Maenhoudt","year":"2020","unstructured":"Maenhoudt N, Defraye C, Boretto M, Jan Z, Heremans R, Boeckx B, et al. Developing organoids from ovarian cancer as experimental and preclinical models. Stem Cell Rep. 2020;14(4):717\u201329.","journal-title":"Stem Cell Rep"},{"key":"1766_CR45","unstructured":"Barbara A, Crothers, Krishnamurti UG, Birdsong GG, Klepeis V, Movahedi-Lankarani S, Otis CN. Protocol for the examination of specimens from patients with primary tumors of the ovary, fallopian tube, or peritoneum [Internet]. 2023 [cited 2024 Jan 2]. Available from: https:\/\/documents.cap.org\/protocols\/Ovary_FT_Perit_1.3.0.1.REL_CAPCP.pdf"},{"issue":"6378","key":"1766_CR46","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fern\u00e1ndez-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic Gastrointestinal cancers. Science. 2018;359(6378):920\u20136.","journal-title":"Science"},{"issue":"5","key":"1766_CR47","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.celrep.2018.07.001","volume":"24","author":"S Nuciforo","year":"2018","unstructured":"Nuciforo S, Fofana I, Matter MS, Blumer T, Calabrese D, Boldanova T, et al. Organoid models of human liver cancers derived from tumor needle biopsies. Cell Rep. 2018;24(5):1363\u201376.","journal-title":"Cell Rep"},{"issue":"6","key":"1766_CR48","doi-asserted-by":"publisher","first-page":"e104013","DOI":"10.15252\/embj.2019104013","volume":"39","author":"K Hoffmann","year":"2020","unstructured":"Hoffmann K, Berger H, Kulbe H, Thillainadarasan S, Mollenkopf H, Zemojtel T, et al. Stable expansion of high-grade serous ovarian cancer organoids requires a low\u2010Wnt environment. EMBO J. 2020;39(6):e104013.","journal-title":"EMBO J"},{"key":"1766_CR49","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","volume":"25","author":"O Kopper","year":"2019","unstructured":"Kopper O, Witte CJ, De, L\u00f5hmussaar K, Valle-inclan JE, Hami N, Kester L, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019;25:838\u20139.","journal-title":"Nat Med"},{"key":"1766_CR50","doi-asserted-by":"publisher","first-page":"e83867","DOI":"10.7554\/eLife.83867","volume":"12","author":"M Vias","year":"2023","unstructured":"Vias M, Gavarr\u00f3 LM, Sauer CM, Sanders DA, Piskorz AM, Couturier DL, et al. High-grade serous ovarian carcinoma organoids as models of chromosomal instability. Elife. 2023;12:e83867.","journal-title":"Elife"},{"issue":"12","key":"1766_CR51","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.devcel.2023.04.012","volume":"58","author":"W Senkowski","year":"2023","unstructured":"Senkowski W, Gall-Mas L, Falco MM, Li Y, Lavikka K, Kriegbaum MC, et al. A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids. Dev Cell. 2023;58(12):1106\u201321.","journal-title":"Dev Cell"},{"issue":"2","key":"1766_CR52","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1093\/nar\/gky1142","volume":"47","author":"S Haile","year":"2019","unstructured":"Haile S, Corbett RD, Bilobram S, Bye MH, Kirk H, Pandoh P, et al. Sources of erroneous sequences and artifact chimeric reads in next generation sequencing of genomic DNA from formalin-fixed paraffin-embedded samples. Nucleic Acids Res. 2019;47(2):e12.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"1766_CR53","doi-asserted-by":"publisher","first-page":"e2001438","DOI":"10.1371\/journal.pbio.2001438","volume":"15","author":"NE Fusenig","year":"2017","unstructured":"Fusenig NE, Capes-Davis A, Bianchini F, Sundell S, Lichter P. The need for a worldwide consensus for cell line authentication: experience implementing a mandatory requirement at the international journal of cancer. PLoS Biol. 2017;15(4):e2001438.","journal-title":"PLoS Biol"},{"issue":"5","key":"1766_CR54","doi-asserted-by":"publisher","first-page":"e13029","DOI":"10.1111\/cpr.13029","volume":"54","author":"J Mei","year":"2021","unstructured":"Mei J, Tian H, Huang HS, Hsu CF, Liou Y, Wu N, et al. Cellular models of development of ovarian high-grade serous carcinoma: A review of cell of origin and mechanisms of carcinogenesis. Cell Prolif. 2021;54(5):e13029.","journal-title":"Cell Prolif"},{"issue":"1","key":"1766_CR55","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3324\/haematol.2021.280294","volume":"108","author":"M Wagstaff","year":"2023","unstructured":"Wagstaff M, Tsaponina O, Caalim G, Greenfield H, Milton-Harris L, Mancini EJ, et al. Crosstalk between b-catenin and WT1 signaling activity in acute myeloid leukemia. Haematologica. 2023;108(1):283\u20139.","journal-title":"Haematologica"},{"issue":"17","key":"1766_CR56","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1101\/gad.9.17.2143","volume":"9","author":"S Maheswaran","year":"1995","unstructured":"Maheswaran S, Englert C, Bennett P, Heinrich G, Haber DA. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev. 1995;9(17):2143\u201356.","journal-title":"Genes Dev"},{"key":"1766_CR57","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fnmol.2011.00004","volume":"4","author":"H Scholz","year":"2011","unstructured":"Scholz H, Kirschner KM. Oxygen-Dependent gene expression in development and cancer: lessons learned from the wilms\u2019 tumor gene, WT1. Front Mol Neurosci. 2011;4:4.","journal-title":"Front Mol Neurosci"},{"issue":"6","key":"1766_CR58","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","volume":"169","author":"R Nusse","year":"2017","unstructured":"Nusse R, Clevers H. Wnt\/\u03b2-Catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985\u201399.","journal-title":"Cell"},{"issue":"2","key":"1766_CR59","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00428-021-03151-0","volume":"479","author":"L Annaratone","year":"2021","unstructured":"Annaratone L, De Palma G, Bonizzi G, Sapino A, Botti G, Berrino E, et al. Basic principles of biobanking: from biological samples to precision medicine for patients. Virchows Arch. 2021;479(2):233\u201346.","journal-title":"Virchows Arch"},{"key":"1766_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ygyno.2024.07.001","volume":"189","author":"O Graham","year":"2024","unstructured":"Graham O, Rodriguez J, Abbott R, Lomonosova E, Fashemi B, Drexler R, et al. A toolkit for a modern gynecologic oncology tissue bank. Gynecol Oncol. 2024;189:1\u20138.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"1766_CR61","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41419-024-07090-x","volume":"15","author":"S von der Heyde","year":"2024","unstructured":"von der Heyde S, Raman N, Gabelia N, Matias-Guiu X, Yoshino T, Tsukada Y, et al. Tumor specimen cold ischemia time impacts molecular cancer drug target discovery. Cell Death Dis. 2024;15(9):691.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1766_CR62","first-page":"100944","volume":"14","author":"DJ Pisapia","year":"2017","unstructured":"Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, et al. Next-Generation rapid autopsies enable tumor evolution tracking and generation of preclinical models. JCO Precis Oncol. 2017;14(1):100944.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"1766_CR63","doi-asserted-by":"publisher","first-page":"100220","DOI":"10.1016\/j.xpro.2020.100220","volume":"2","author":"CJ Phifer","year":"2021","unstructured":"Phifer CJ, Bergdorf KN, Bechard ME, Vilgelm A, Baregamian N, McDonald OG, et al. Obtaining patient-derived cancer organoid cultures via fine-needle aspiration. STAR Protoc. 2021;2(1):100220.","journal-title":"STAR Protoc"},{"issue":"3","key":"1766_CR64","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41591-024-02807-z","volume":"30","author":"MFM Gerli","year":"2024","unstructured":"Gerli MFM, Cal\u00e0 G, Beesley MA, Sina B, Tullie L, Sun KY, et al. Single-cell guided prenatal derivation of primary fetal epithelial organoids from human amniotic and tracheal fluids. Nat Med. 2024;30(3):875\u201387.","journal-title":"Nat Med"},{"key":"1766_CR65","doi-asserted-by":"publisher","first-page":"1061388","DOI":"10.3389\/fimmu.2022.1061388","volume":"13","author":"J Yuan","year":"2022","unstructured":"Yuan J, Li X, Yu S. Cancer organoid co-culture model system: novel approach to guide precision medicine. Front Immunol. 2022;13:1061388.","journal-title":"Front Immunol"},{"key":"1766_CR66","doi-asserted-by":"crossref","unstructured":"Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C et al. ESGO\u2013ESMO\u2013ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol. 2024;35(3):248\u201366.","DOI":"10.1016\/j.annonc.2023.11.015"},{"issue":"4","key":"1766_CR67","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/PGP.0b013e318264ae09","volume":"32","author":"E Mahe","year":"2013","unstructured":"Mahe E, Tang S, Deb P, Sur M, Lytwyn A, Daya D. Do deeper sections increase the frequency of detection of serous tubal intraepithelial carcinoma (STIC) in the sectioning and extensively examining the fimbriated end (SEE-FIM) protocol? Int J Gynecol Pathol. 2013;32(4):353\u20137.","journal-title":"Int J Gynecol Pathol"},{"issue":"11","key":"1766_CR68","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1002\/stem.1207","volume":"30","author":"DY Paik","year":"2012","unstructured":"Paik DY, Janzen DM, Schafenacker AM, Velasco VS, Shung MS, Cheng D, et al. Stem-like epithelial cells are concentrated in the distal end of the fallopian tube: A site for injury and serous cancer initiation. Stem Cells. 2012;30(11):2487\u201397.","journal-title":"Stem Cells"},{"issue":"2","key":"1766_CR69","doi-asserted-by":"publisher","first-page":"108978","DOI":"10.1016\/j.celrep.2021.108978","volume":"35","author":"HQ Dinh","year":"2021","unstructured":"Dinh HQ, Lin X, Abbasi F, Nameki R, Haro M, Olingy CE, et al. Single-cell transcriptomics identifies gene expression networks driving differentiation and tumorigenesis in the human fallopian tube. Cell Rep. 2021;35(2):108978.","journal-title":"Cell Rep"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01766-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01766-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01766-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T09:15:09Z","timestamp":1757409309000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-025-01766-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1766"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01766-4","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"15 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in strict accordance with ethical guidelines. Approval was obtained from the Ethics Committee of CUF Descobertas Hospital, Lisbon, Portugal, under the reference \u201cOVARY\u201d (CE\u2013 026\/20\u2013 JMS\/is). Informed consent was obtained from all participants involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}